Currency In USD
| Previous Close | 0.96 |
| Open | 0.99 |
| Day High | 1 |
| Day Low | 0.95 |
| 52-Week High | 2.5 |
| 52-Week Low | 0.5 |
| Volume | 750,731 |
| Average Volume | 112,412 |
| Market Cap | 42M |
| PE | -1.64 |
| EPS | -0.58 |
| Moving Average 50 Days | 1.02 |
| Moving Average 200 Days | 0.94 |
| Change | -0.01 |
Elutia Regains Compliance with Nasdaq Listing Requirements
GlobeNewswire Inc.
Mar 04, 2026 1:00 PM GMT
GAITHERSBURG, Md., March 04, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it has received notice from Nasdaq that Elutia has regained complia
Elutia Selects Pete Ligotti as CCO to Lead the Commercial Launch of NXT-41x and Transform Post-Mastectomy Care in the $1.5B U.S. Breast Surgery Market
GlobeNewswire Inc.
Mar 02, 2026 1:00 PM GMT
GAITHERSBURG, Md., March 02, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced the appointment of Pete Ligotti as Chief Commercial Officer. Mr. Ligotti
Elutia to Report Fourth Quarter 2025 Financial Results on Wednesday, March 11, 2026
GlobeNewswire Inc.
Feb 25, 2026 9:05 PM GMT
GAITHERSBURG, Md., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its fourth quarter 2025 financial results after mark